NEW YORK, Dec. 1, 2016 /PRNewswire/ -- Women's Health Diagnostics Market by Application (Prenatal Testing, Down Syndrome, HPV, Fertility Test, Pregnancy Test, Urinary Tract Infections, Osteoporosis, Breast, Cervical and Ovarian Cancer Test) End User (Hospitals, Home Care) - Forecast to 2021 The global women's health diagnostics market is projected to reach USD 36.64 billion by 2021, growing at a CAGR of around 7.9% during the forecast period. Growth in this market can be attributed to a number of factors such as high prevalence of infectious diseases in women, rising incidence of chronic and lifestyle-related disorders and increasing awareness about fertility testing in women and initiatives taken by government and health organizations. Moreover, the increasing adoption of point-of-care diagnostic testing and the increasing number of diagnostic and imaging centers are also expected to play a major role in market growth. However, high cost of diagnostic solutions and lack of trained laboratory technicians are some of the factors restraining the growth of this market. The women health diagnostics market in this report is segmented by application and end users. Based on application, the market is segmented into osteoporosis testing, ovarian cancer testing, cervical cancer testing, breast cancer testing, pregnancy & ovulation testing, prenatal genetic screening & carrier testing, infectious disease testing, sexually transmitted disease (STD) testing, and ultrasound. The osteoporosis segment is further divided into bone densitometry and in vitro blood tests. The ovarian cancer segment is divided into tumor marker tests, diagnostic imaging tests and others. The cervical cancer segment is sub segmented into PAP smear testing and HPV testing. The breast cancer testing segment is further divided into mammography systems, tumor marker tests, blood chemistries & blood cell count tests, biopsies, and other diagnostic imaging tests. Pregnancy and fertility testing market is sub segmented into lab-based testing, pregnancy self-test and ovulation prediction kits, ovulation prediction kits, fertility monitors and thermometers. The prenatal genetic screening & carrier testing segment is further divided into cystic fibrosis, Down syndrome and Edward syndrome, TORCH infections and others (fragile x-syndrome & tay-sachs diseases). Further on, the infectious disease testing market segment is sub segmented into methicillin-resistant staphylococcus aurea (MRSA), urinary tract infections (vaginal pH & vaginitis), hepatitis, tuberculosis and streptococcus testing. The sexually transmitted disease testing segment comprises Chlamydia Trachomatis and Neisseria Gonorrohoeae testing, HIV testing and other STD testing. The ultrasound segment covers breast imaging and ob/gyn imaging. In 2015, the breast cancer testing product segment accounted for the largest share of the women health diagnostics market. This market is primarily driven by the increasing incidence of breast cancer and rising awareness about advanced breast cancer diagnostic techniques. Based on end user, the women health diagnostics market is segmented into three segments, namely, hospitals & clinics, home care, and diagnostic & imaging centers.